ASH 2021 | Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AML
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the rationale of OMNIVERSE, a Phase Ib/II study evaluating the safety, tolerability and preliminary efficacy of oral azacitidine in combination with venetoclax in elderly or unfit patients with relapsed/refractory (R/R) or newly diagnosed acute myeloid leukemia (AML) ineligible to receive intensive chemotherapy (NCT04887857). The combination of hypomethylating agents (HMA) with venetoclax is the standard of care (SOC) for older and unfit patients with AML. Since this treatment is administered every month over an extended period, it would be advantageous to develop a fully oral treatment regimen for this patient population. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
